Startups
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future.
For additional information, visit the Company's website, www.phiopharma.com.
Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future.
For additional information, visit the Company's website, www.phiopharma.com.
Overview
Location
United States, Massachusetts, Marlborough
Employees
11-50
Founded date
2012
Mentions in press and media 24
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 6, 2026 | Phio Pharmaceuticals Reports Q3 2026 Results and Business Update as It Advances PH-762 Toward Phase 2b Study | PH-762 Achieves Key Milestones, Including Commercial-Scale cGMP Manufacturing, Long-Term Toxicology Study Treatment, and FDA Regulatory Submissions Phio Pharmaceuticals Corp. (NASDAQ:PHIO) We have successfully executed on critical developme... |
| Oct 7, 2026 | Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026 | Phio Pharmaceuticals CEO Robert Bitterman will present the Company’s INTASYL® siRNA therapeutic platform at the Global Markets Virtual Forum on October 8. Phio invites individual and institutional investors as well as advisors and analysts,... |
| Oct 5, 2026 | Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference | Phio Pharmaceuticals CEO Robert Bitterman will present the Company’s INTASYL® siRNA platform and PH-762 clinical program at NIBA’s 153rd Conference on October 7. Phio Pharmaceuticals heads to NIBA’s 153rd Conference to highlight its differe... |
| Sep 23, 2026 | Phio Pharmaceuticals to Present Clinical Development Update & Upcoming Catalysts at Life Sciences Future 2026 Conference | Phio Pharmaceuticals will present an update on its completed Phase 1b PH-762 study and planned next steps at the Life Sciences Future 2026 Conference on September 30. Phio Pharmaceuticals CEO Robert Bitterman will discuss PH-762’s clinical ... |
| Sep 14, 2026 | Phio Announces PH-762 Milestone with FDA Submission Supporting Clinical Development in Cutaneous Squamous Cell Carcinoma | Phio Pharmaceuticals submitted a comprehensive briefing package to the FDA following completion of its Phase 1b PH-762 study, supporting the program’s next stage of clinical development. Phio advances PH-762 toward a planned Phase 2b neoadj... |
| Sep 12, 2026 | Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Phio Pharmaceuticals (Nasdaq: PHIO) management will meet investors one-on-one at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The H.C. Wainwright 28th Annual Global Investment Conference is taking place Septembe... |
| Aug 13, 2026 | Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein | Phio Pharmaceuticals receives a U.S. Notice of Allowance for a patent covering PH-894, expanding protection for its INTASYL® gene-silencing platform. Phio strengthens its intellectual property portfolio with a U.S. patent allowance for PH-8... |
| Jul 17, 2026 | Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision | Phio Pharmaceuticals strengthens its global intellectual property portfolio with new patent allowances and a grant across the U.S., Canada, and Japan for its INTASYL® platform. New patent milestones expand protection for Phio Pharmaceutical... |
| Jun 25, 2026 | Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 | Newly manufactured supply will support upcoming clinical trial in next development phase The start of commercial-scale PH-762 manufacturing marks a key milestone as Phio advances its lead INTASYL® siRNA candidate following completion of its... |
Show more
Reviews 0
FAQ about Phio Pharmaceuticals Corp.
When was Phio Pharmaceuticals Corp. founded?
Phio Pharmaceuticals Corp. was founded in 2012.
What has the press written about Phio Pharmaceuticals Corp.?
Parsers VC has collected 24 articles mentioning Phio Pharmaceuticals Corp., among them “Phio Pharmaceuticals Reports Q3 2026 Results and Business Update as It Advances PH-762 Toward Phase 2b Study” (Nov 6, 2026) and “Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026” (Oct 7, 2026).
Is Phio Pharmaceuticals Corp. still active?
Yes, Phio Pharmaceuticals Corp. is active; its latest activity on Parsers VC dates from Nov 6, 2026.